EGFR and non-small cell lung carcinoma: NSCLC cell lines carrying either in-frame EGFR deletions (E746-A750del in PC9 and H4006; K745-E749del+A750K in H1650) or a site-specific EGFR mutation (L858R mutation in H4011) were sensitive to treatment with the first-generation EGFR TKIs gefitinib and erlotinib, as expected, as indicated by decreased expansion over 72 hours in culture (Figure 1A).